3MSS

Abl kinase in complex with imatinib and fragment (FRAG2) in the myristate site

Summary for 3MSS

Entry DOI	10.2210/pdb3mss/pdb
Related	3MS9
Descriptor	Tyrosine-protein kinase ABL1, 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE, O-benzyl-N-methyl-L-tyrosinamide, ... (4 entities in total)
Functional Keywords	kinase, fragment-based screening, fbs, transferase, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological source	Mus musculus (mouse)
Cellular location	Cytoplasm, cytoskeleton: P00520
Total number of polymer chains	4
Total formula weight	138085.92
Authors	Cowan-Jacob, S.W.,Rummel, G.,Fendrich, G. (deposition date: 2010-04-29, release date: 2010-05-26, Last modification date: 2023-09-06)
Primary citation	Jahnke, W.,Grotzfeld, R.M.,Pelle, X.,Strauss, A.,Fendrich, G.,Cowan-Jacob, S.W.,Cotesta, S.,Fabbro, D.,Furet, P.,Mestan, J.,Marzinzik, A.L. Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay. J.Am.Chem.Soc., 132:7043-7048, 2010 Cited by PubMed: 20450175 DOI: 10.1021/ja101837n PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (1.95 Å)

Structure validation